AIM: To determine any correlation between magnetic resonance spectroscopy (MRS) pattern of high-grade glioma before, during, and after radiotherapy (RT) with overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS: Twenty-six patients prospectively underwent surgery and RT to 60 Gy. MRS was performed before RT, at week 4 of RT, and 2 months post-RT. Normalized and relative metabolite ratios were evaluated. Patients were grouped according to similar evolving MRS patterns and analyzed for differences in OS and PFS. RESULTS: Significant decreases in tumor choline/N-acetyl-aspartate and normalized choline were observed from baseline to post-RT. After a median follow-up of 22.9 months, patients with >40% decrease in normalized choline from week 4 during RT to 2 months post-RT had a significantly worse median OS (9.1 months vs. not reached, p<0.00001) and PFS (5.8 vs. 19.8 months, p=0.0018). CONCLUSION: The change in normalized choline at 2 months post-RT was highly prognostic for PFS and OS. This may allow more individualized response-based treatment.
AIM: To determine any correlation between magnetic resonance spectroscopy (MRS) pattern of high-grade glioma before, during, and after radiotherapy (RT) with overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS: Twenty-six patients prospectively underwent surgery and RT to 60 Gy. MRS was performed before RT, at week 4 of RT, and 2 months post-RT. Normalized and relative metabolite ratios were evaluated. Patients were grouped according to similar evolving MRS patterns and analyzed for differences in OS and PFS. RESULTS: Significant decreases in tumorcholine/N-acetyl-aspartate and normalized choline were observed from baseline to post-RT. After a median follow-up of 22.9 months, patients with >40% decrease in normalized choline from week 4 during RT to 2 months post-RT had a significantly worse median OS (9.1 months vs. not reached, p<0.00001) and PFS (5.8 vs. 19.8 months, p=0.0018). CONCLUSION: The change in normalized choline at 2 months post-RT was highly prognostic for PFS and OS. This may allow more individualized response-based treatment.
Authors: T Jaspan; P S Morgan; M Warmuth-Metz; E Sanchez Aliaga; D Warren; R Calmon; J Grill; D Hargrave; J Garcia; G Zahlmann Journal: AJNR Am J Neuroradiol Date: 2016-04-28 Impact factor: 3.825
Authors: Yan Li; Janine M Lupo; Rupa Parvataneni; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson Journal: Neuro Oncol Date: 2013-02-07 Impact factor: 12.300
Authors: Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung Journal: Med Phys Date: 2021-05-20 Impact factor: 4.071
Authors: Andrew A Maudsley; Ovidiu C Andronesi; Peter B Barker; Alberto Bizzi; Wolfgang Bogner; Anke Henning; Sarah J Nelson; Stefan Posse; Dikoma C Shungu; Brian J Soher Journal: NMR Biomed Date: 2020-04-29 Impact factor: 4.044
Authors: Maria Tolia; Dimitrios Verganelakis; Nikolaos Tsoukalas; George Kyrgias; Matilda Papathanasiou; Eftichia Mosa; Ioannis Kokakis; John R Kouvaris; George Pissakas; Kyriaki Pistevou-Gombaki; Nikolaos Kelekis; Vasileios Kouloulias Journal: Biomed Res Int Date: 2015-08-03 Impact factor: 3.411